| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President &CEO | Director
2 companies
Hawryluk P. Kent is a President &CEO at MBX, with reported holdings spanning 2 companies. Recent filings cover 5 purchases and 1 sale. Those positions are worth an estimated $22.3M at current prices.
Our model assigns Hawryluk P. Kent a strong insider score of 80/100, based on 4 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +100.0%.
Hawryluk P. Kent's largest disclosed position is in MBX as President &CEO, worth about $21.5M. Net of sales, the recent Form 4 record there shows accumulation of 87,893 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | MBX Mbx Biosciences, Inc. | President &CEO | Sell | 607 | $29.54 | $17,930.78 | - | +120.1% | - | |
| Mar 13, 2026 | MBX Mbx Biosciences, Inc. | President &CEO | Buy | 18,500 | $28.41 | $525,662.70 | +4.0% | +33.0% | - | |
| Oct 20, 2025 | MBX Mbx Biosciences, Inc. | President &CEO | Buy | 20,000 | $13.64 | $272,790.00 | +4.5% | +203.2% | +276.0% | |
| Feb 4, 2025 | MBX Mbx Biosciences, Inc. | President &CEO | Buy | 50,000 | $10.69 | $534,500.00 | +12.6% | +10.4% | +251.1% | |
| Mar 10, 2017 | MTVA Metavia Inc. | Director | Buy | 25,000 | $9.47 | $236,750.00 | +43.9% | - | - | |
| Aug 10, 2016 | MTVA Metavia Inc. | Director | Buy | 25,000 | $10.00 | $250,000.00 | +78.4% | - | - |